Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcript
ARWR - Arrowhead Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$91.00
DETAILS
HIGH:
$110.00
LOW:
$46.00
MEDIAN:
$100.00
CONSENSUS:
$91.00
UPSIDE:
6.13%
Stock News
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets.
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). REDEMPLO is the first and only siRNA medicine authorized by the EC for adults with FCS, diagnosed either by the presence of clinical crit.
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule (TRiM™) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company's clinical candidates and externa.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction
Arrowhead Pharmaceuticals NASDAQ: ARWR executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through its TRiM, or Targeted RNAi Molecule, platform.
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global He
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global Healthcare Conference – June 2-4, 2026 Type: Fireside Chat Presentation Date/Time: June 3, 2026, 8:10 am EDT Goldman Sachs 47th Annual Global Healthcare Conference – June 8-10, 2026 Type: Fireside Chat Presentation Date/Time: June 10, 2026, 9:00 am EDT Presentation materials and webcast links, if applicable,.
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company's invest
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The data presented at the European Association for the Study of the Liver Congress (EASL 2026) demonstrate that ARO-INHBE treatment led to clinically meaningf.
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented new positive clinical data for plozasiran supporting its use in patients with moderate-to-severe renal impairment or moderate hepatic impairment without the need for dose adjustment, and a case report suggesting that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride (TG) levels through the term of a pregnancy. The data were presented in two oral.
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today presented new positive clinical data for plozasiran supporting its use in patients with moder
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum
Arrowhead Pharmaceuticals NASDAQ: ARWR executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets' 2026 Global Healthcare Conference.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near
Arrowhead Pharmaceuticals NASDAQ: ARWR is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation with BofA pharma and biotech analyst Jason Gerberry at the BofA Annual Healthcare Conference.
Arrowhead Pharmaceuticals: A True Inflection Point Has Arrived
Arrowhead Pharmaceuticals presents a compelling bull case with a strong pipeline and a new commercialization status thanks to REDEMPLO FDA approval. ARWR's cardiometabolic pipeline, including REDEMPLO's potential updating and ARO-DIMER-PA's dual-target RNAi, supports future growth and market reach. The CNS drug ARO-MAPT that targets tauopathies linked to diseases like Alzheimer's will produce Phase 1 data in 2H 2026. This could drive a positive valuation rerating for ARWR.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to show strong execution in meeting and exceeding our commercial, R&D, and corporate goals. The company is on extremely strong footing to continue to drive growth in the near-term with numerous opport.
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowhead's clinical stage RNA interference (RNAi) therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH). “The early clinical data for ARO-PNPLA3 h.
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the events in which it is scheduled to participate throughout the month of May, 2026.
Price Targets
Arrowhead price target raised to $46 from $35 at Bernstein
$46.00
(was $79.04)
Bernstein
Arrowhead price target raised to $90 from $80 at Chardan
$90.00
(was $77.95)
Chardan Capital
Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley
$100.00
(was $69.25)
Morgan Stanley
Arrowhead price target lowered to $78 from $81 at Morgan Stanley
$78.00
(was $66.64)
Morgan Stanley
Morgan Stanley on Arrowhead Pharma (ARWR): 'we are encouraged by the on track progress for the ARO-DIMER-PA program'
$81.00
(was $67.02)
Robert W. Baird
Arrowhead price target raised to $100 from $85 at H.C. Wainwright
$100.00
(was $68.80)
H.C. Wainwright
'Arrowhead Pharma (ARWR) Raises $930 Million to Launch Redemplo'; PT Raised at Piper Sandler
$110.00
(was $68.03)
UBS
Arrowhead price target raised to $110 from $100 at Piper Sandler
$110.00
(was $65.93)
Piper Sandler
Arrowhead price target raised to $81 from $48 at Morgan Stanley
$81.00
(was $70.81)
Morgan Stanley
Arrowhead price target raised to $80 from $60 at Chardan
$80.00
(was $70.81)
Chardan Capital
Arrowhead Pharma (ARWR) PT Raised at Bernstein Ahead of Obesity Data Update
$35.00
(was $66.39)
William Pickering
·
Tudor Pickering
Arrowhead price target raised to $35 from $17 at Bernstein
$35.00
(was $67.25)
Bernstein
Arrowhead price target raised to $100 from $70 at Piper Sandler
$100.00
(was $64.66)
Edward Tenthoff
·
Piper Sandler
Arrowhead price target raised to $80 from $52 at RBC Capital
$80.00
(was $68.91)
RBC Capital
Arrowhead price target raised to $85 from $80 at H.C. Wainwright
$85.00
(was $56.25)
H.C. Wainwright
Arrowhead price target raised to $48 from $45 at Morgan Stanley
$48.00
(was $46.79)
Morgan Stanley
Arrowhead Pharma (ARWR) PT Lowered to $24 at Bernstein SocGen Group
$24.00
(was $25.81)
William Pickering
·
Bernstein
Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
$60.00
(was $12.90)
Keay Nakae
·
Loop Capital Markets
Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
$27.00
(was $22.91)
David Lebowitz
·
Citigroup
Arrowhead Pharma (ARWR) PT Lowered to $60 at H.C. Wainwright
$60.00
(was $12.77)
Patrick Trucchio
·
H.C. Wainwright